Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by several executives on February 9, 2012, at a price of 1397.64 pence per share through the Company's ShareReward Plan. The transactions include both personal contributions and matching company contributions:
- Sir Andrew Witty: Acquired 9 shares (personal) and 9 shares (company match).
- Mr S Dingemans: Acquired 9 shares (personal) and 9 shares (company match).
- Mr S M Bicknell: Acquired 9 shares (personal) and 9 shares (company match).
- Mr E J Gray: Acquired 9 shares (personal) and 9 shares (company match).
- Mr D S Redfern: Acquired 9 shares (personal) and 9 shares (company match).
- Ms C Thomas: Acquired 9 shares (personal) and 9 shares (company match).
- Mr P C Thomson: Acquired 6 shares (personal) and 6 shares (company match).
- Dr P J T Vallance: Acquired 9 shares (personal) and 9 shares (company match).
- Mrs V A Whyte: Acquired 9 shares (personal) and 9 shares (company match).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of share purchases in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the share price of 1397.64 pence per Ordinary share on February 9, 2012.
- Confirm the total number of shares acquired by each listed executive under the ShareReward Plan.
- Review the company's broader annual report (Form 20-F) for comprehensive financial performance data not included in this filing.